The effect of the
direct renin inhibitor enalkiren (Abbott Laboratories) was examined in 8 healthy patients with
essential hypertension. With an unrestricted
sodium diet, plasma
renin concentration was inhibited within 10 minutes by intravenous
enalkiren and remained essentially undetectable for greater than or equal to 6 hours (11.9 +/- 4 to 1.0 +/- 0.6 ng
angiotensin I/ml/hour, p less than 0.05). Mean arterial blood pressure declined gradually (108 +/- 5 to 84 +/- 4 mm Hg, p = 0.02), as did plasma
aldosterone concentration (14.4 +/- 3.8 to 4.4 +/- 0.8 ng/dl, p = 0.03), whereas plasma immunoreactive active
renin concentration increased progressively (35 +/- 14 to 160 +/- 60 pg/ml, p greater than 0.05). Urinary excretion of the stable metabolite of
prostacyclin (6-keto-prostaglandin F1 alpha) decreased slightly, but not significantly (42 +/- 10 to 33 +/- 11 ng/g
creatinine, p = 0.13). The addition of a
diuretic decreased baseline blood pressure and increased baseline plasma
renin and
aldosterone values. Blood pressure responses to
enalkiren were slightly (though not significantly) greater than those observed before
diuretic administration. We conclude that
enalkiren is effective in decreasing blood pressure and in inhibiting the
renin system, without significantly altering urinary
prostacyclin excretion, in patients with
essential hypertension. These results suggest that the
renin system contributes to the maintenance of elevated blood pressure in some patients with
essential hypertension.